Home Finance specialist Mydecine partners with Combat Stress to treat post-traumatic stress disorder in veterans

Mydecine partners with Combat Stress to treat post-traumatic stress disorder in veterans


The study further supports the expansion of clinical trials of MYCO-001 for the treatment of PTSD among the veteran population.

DENVER, Jan. 24, 2022 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company to transform the treatment of mental health and addiction disorders, today announced a partnership with Combat Stress (Combat Stress) and King’s College London to use psilocybin as part of psychoactive-assisted psychotherapy treatment for post-traumatic stress disorder (PTSD) in veterans. Combat Stress will be one of the sites for Mydecine’s upcoming clinical trials.

Fight stress is the leading veterans’ mental health charity in the UK, providing treatment and support to former servicemen for over a century. They offer a range of specialized online, community-based, outpatient and residential mental health services to veterans with complex mental health issues related to their military service.

Professor Dominic Murphy, head of research at Combat Stress and president of the UK Psychological Trauma Society, has been appointed principal investigator for the study which will use Mydecine’s lead psilocybin drug candidate, MYCO-001, to complement psychotherapy to treat severe PTSD in veterans who have otherwise resisted traditional forms of therapy. The data gathered from the study will further advance Mydecine’s drug development pipeline and ability to bring a much-needed new treatment to market.

“I’m really excited to be leading this study at Combat Stress,” Professor Murphy said. “We know that the gold standard treatments for PTSD, provided by Combat Stress and other organizations, work for most veterans. However, for a minority, their symptoms do not improve. This collaboration holds great potential for research focused on innovative new therapies that offer important opportunities to bring hope to veterans who are still living with the trauma of their military experiences.

Mydecine’s chief medical officer, Dr Rakesh Jetly, said: “The team is excited to be conducting studies within the veteran population where help is most needed. In my 31 years as a medical officer and psychiatrist in the Canadian Armed Forces, I have seen firsthand the impact of PTSD on our veterans and their families. Unfortunately, many soldiers and veterans do not respond to evidence-based treatments readily available to them, and research is ongoing for new, safe and effective treatments. Our troops fight and sacrifice together, so it makes sense that we help them heal together.

Mydecine CEO Josh Bartch said, “This partnership is another important opportunity to expand our clinical trials and fulfill our mission to develop safe and effective alternative medicine that people can trust. There is a great unmet need for treatment of PTSD and other mental health issues, particularly within the veteran population, and this partnership demonstrates the tremendous progress we continue to make in bringing assisted psychotherapies by psychoactivity at the forefront of the market and bring hope. for anyone struggling with these conditions.

Stay informed and subscribe to the Mydecine newsletter by scroll down this page.

About the Medicine Innovations Group

Mydecine Innovations Group ™ (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology and digital technology company that develops new, innovative first and second generation therapies for the treatment of mental health and drug addiction through world-class technology and drug development infrastructure. Mydecine Innovations Group was founded in 2020 on the guiding principle that there is a significant unmet need and lack of innovation in mental health and treatment settings. Mydecine Innovations Group is dedicated to the effective development of innovative therapies to treat PTSD, depression, anxiety, addiction and other mental health disorders. Mydecine Innovations Group’s business model combines clinical trials and data outcomes, technology, scientific and regulatory expertise with a focus on psychedelic therapy supported by other novel molecules with differentiated therapeutic potential. By collaborating with some of the world’s leading authorities bound by best practices, Mydecine Innovations Group aims to responsibly accelerate the development of new medicines on its platforms, seeking to effectively treat and ultimately change the way we treat disorders of Mental Health. The vision of Mydecine Innovations Group is to bridge the current gap between what the cognitive health system currently provides and the needs of patients. Mydecine Innovations Group is headquartered in Denver, Colorado, USA, and international offices in Leiden, The Netherlands.

Learn more about: www.mydecine.com and follow the company on Twitter, instagram, and LinkedIn.

For more information please contact:

Contact with investors and the media
Morgan Kervitsky, Chief Marketing Officer
(720) 689-4638
[email protected]

On behalf of the Board of Directors:
Joshua Bartch, General Manager
[email protected]

For additional information about Mydecine Innovations Group, Inc., please see the company’s profile on SEDAR at www.sedar.com or visit the company’s website at www.mydecine.com.

This press release contains forward-looking information within the meaning of Canadian securities laws concerning the Company and its business, which relates to future events or future performance and reflects management’s current expectations and assumptions. Often, but not always, forward-looking information can be identified by the use of words such as “expects”, “intends”, “anticipates”, “believes” or variations (including variations negative) of these words and expressions, or declare that certain actions, events or results “could”, “might”, “would” or “would” be undertaken, occur or be achieved. These forward-looking statements reflect management’s current beliefs and are based on assumptions made by the Company and information currently available to it. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected, including, without limitation, risks relating to the COVID-19 pandemic, the availability and continuity of financing, the Company’s ability to adequately protect and enforce its intellectual property, the Company’s ability to put its products into commercial production, the continued growth of global adaptive medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive marketplace regarding the development, production, sale and use of the Company’s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information, there may be other factors that cause results not to be those anticipated, estimated or expected. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof, and the Company undertakes no obligation to update or revise them to reflect new events or circumstances, except as required by applicable securities laws.